Oxcarbazepine monotherapy in carbamazepine-unresponsive trigeminal neuralgia.
The objective of this prospective open-label study was to evaluate the efficacy and tolerability of oxcarbazepine in trigeminal neuralgia (TN) unresponsive to treatment with the standard antiepileptic drug, carbamazepine. Thirty-five patients with idiopathic TN, who underwent treatment with oxcarbazepine monotherapy for at least 12 weeks, were studied. Pain was assessed using mean pain frequency, responder rate, pain-free patients and clinical global impression. The mean maintenance dose was 773.7 mg/day. There was a significant decrease in the mean of the main scores following 12 weeks of treatment (p<0.05) compared with baseline. Oxcarbazepine was effective from the first month of treatment. There was a significant reduction in pain frequency, leading to improvements in patient satisfaction. In general, oxcarbazepine was well tolerated. Oxcarbazepine appears to be an important alternative therapeutic approach for patients affected by TN. This study adds to the existing literature arriving at the same findings.
Gomez-Arguelles
J M
JM
Department of Neurology, Sanatorio De Nuestra Señora del Rosario, Principe De Vergara 53, 28006 Madrid, Spain.
Dorado
R
R
Sepulveda
J M
JM
Herrera
A
A
Arrojo
F Gilo
FG
Aragón
E
E
Huete
C Ruiz
CR
Terrón
C
C
Anciones
B
B
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000927:Anticonvulsants / Q000627:therapeutic use*; D002220:Carbamazepine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013997:Time Factors; D014277:Trigeminal Neuralgia / Q000188:drug therapy*
D000927:Anticonvulsants; C476610:oxcarbamazepine; D002220:Carbamazepine